Micron Biomedical, a clinical-stage biotech company developing next-generation thermostable vaccines and therapeutics, announced a vaccine development agreement with the U.S. Centers for Disease Control and Prevention (CDC) to support the continued fight against rotavirus. Under the contract terms, Micron Biomedical will advance development of a novel live-attenuated rotavirus vaccine delivered through the skin.
Micron Biomedical, a clinical-stage biotech company developing next-generation thermostable vaccines and therapeutics, announced a vaccine development agreement with the U.S. Centers for Disease Control and Prevention (CDC) to support the continued fight against rotavirus. Under the contract terms, Micron Biomedical will advance development of a novel live-attenuated rotavirus vaccine delivered through the skin.